

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited
和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS TO PRESENT UPDATED RESULTS
FROM THE PHASE 2 STUDY OF IRPAGRATINIB IN
COMBINATION WITH ATEZOLIZUMAB FOR
THE TREATMENT OF ADVANCED HCC
AT THE 2025 ESMO GI CONGRESS

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”), a subsidiary of the Company, announced that updated results from the phase 2 study of irpagratinib (ABSK-011) in combination with atezolizumab for the treatment of patients with advanced hepatocellular carcinoma (“**HCC**”) will be presented at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress (“**2025 ESMO GI Congress**”), taking place in Barcelona, Spain from July 2, 2025 to July 5, 2025 (local time). The oral presentation will highlight the safety and efficacy of irpagratinib in combination with atezolizumab in both treatment-naïve and previously treated FGF19+ HCC patients. **The treatment combination with irpagratinib showcases an objective response rate of ≥50% and a median progression-free survival of ≥7 months.** These results further demonstrate the clinical benefit of irpagratinib in both previously treated and treatment-naïve settings, offering renewed hope for patients with advanced HCC.

This is a voluntary announcement made by the Company. The Group cannot guarantee that irpagratinib will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, June 26, 2025

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced HCC at the 2025 ESMO GI Congress

On June 26, 2025, Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**”) announced that updated results from the phase 2 study of irpagratinib (ABSK-011) in combination with atezolizumab for the treatment of patients with advanced hepatocellular carcinoma (“**HCC**”) will be presented at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress (“**2025 ESMO GI Congress**”), taking place in Barcelona, Spain from July 2, 2025 to July 5, 2025 (local time). The oral presentation will highlight the safety and efficacy of irpagratinib in combination with atezolizumab in both treatment-naïve and previously treated FGF19+ HCC patients. The treatment combination with irpagratinib showcases an objective response rate (“**ORR**”) of $\geq 50\%$ and a median progression-free survival (“**PFS**”) of ≥ 7 months. These results further demonstrate the clinical benefit of irpagratinib in both previously treated and treatment-naïve settings, offering renewed hope for patients with advanced HCC.

The details of the oral presentation by Abbisko Therapeutics during the 2025 ESMO GI Congress are as follows:

Title: Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study

Presentation Format: Oral Presentation

Session: Mini Oral session – Innovation in GI cancers

Presentation number: 149MO

Presenter: Qi Cheng

Date: July 2, 2025

Room: Barcelona

Summary:

At the 2025 ESMO GI Congress, Abbisko Therapeutics unveiled updated clinical trial results for the combination of irpagratinib and atezolizumab in patients with FGF19 overexpression HCC. The treatment combination with irpagratinib showcases an ORR of $\geq 50\%$ and a median PFS of ≥ 7 months in the 220 mg BID cohort. These findings highlight the efficacy of this novel combination therapy in treating HCC patients with FGF19 overexpression, a subgroup of patients typically associated with poorer prognosis and less sensitivity to first-line standard-of-care (“**SOC**”) treatments, such as immune checkpoint inhibitors (“**ICIs**”).

Abbisko Therapeutics plans to initiate clinical trials exploring dual and triple combination therapies with irpagratinib in both previously ICI-treated and treatment-naïve patient populations. Abbisko Therapeutics remains committed to advancing combination strategies involving irpagratinib to better address the challenges of HCC and bring renewed hope to patients, and will continue conducting research in this disease area.

Background:

HCC is the most common type of primary liver cancer and ranks as the sixth most prevalent cancer and third leading cause of death worldwide. Dysregulation of FGF19-FGFR4 signaling accounts for approximately 30% of HCC and plays a pivotal role in driving HCC tumorigenesis. Irapratinib is a highly potent and selective FGFR4 inhibitor, with potential to become a first-in-class or best-in-class FGFR4 inhibitor.

Abbisko Therapeutics previously presented phase I clinical data of irapratinib at the 2024 ESMO Annual Meeting, demonstrating promising anti-tumor activity as a single agent with an ORR of 44.8% in FGF19 overexpressed late-line HCC patients.

To further explore the therapeutic potential of irapratinib, Abbisko Therapeutics is conducting a phase 2 clinical trial of irapratinib in combination with atezolizumab. This trial is investigating irapratinib in combination with atezolizumab, a PD-L1 antibody, in FGF19+ advanced HCC patients. At the previous 2024 ESMO GI Congress, Abbisko Therapeutics presented clinical data demonstrating 220mg irapratinib BID in combination with atezolizumab achieved a 50% ORR in FGF19+ HCC patients who had previously received ICI therapy.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.